Advancis cutting workforce by one-third

Advancis Pharmaceutical is on a cost-cutting spree that involves cutting its workforce by one-third and eliminating all nonessential temporary workers. A total of 33 jobs will be cut, including six corporate officer jobs. The company hopes to reduce annual spending by $4.1 million. The changes come on the heels of failures in a second final-stage trial of the company's lead product, a once-a-day amoxicillin formulation.

- read this story from the Baltimore Business Journal for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.